AbbVie Inc. $ABBV Shares Bought by Sustainable Insight Capital Management LLC

Sustainable Insight Capital Management LLC raised its position in shares of AbbVie Inc. (NYSE:ABBV) by 247.0% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 3,512 shares of the company’s stock after buying an additional 2,500 shares during the period. Sustainable Insight Capital Management LLC’s holdings in AbbVie were worth $802,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of ABBV. RKL Wealth Management LLC raised its holdings in shares of AbbVie by 8.1% in the 4th quarter. RKL Wealth Management LLC now owns 17,748 shares of the company’s stock valued at $4,055,000 after buying an additional 1,328 shares during the period. Investment Research Partners LLC raised its holdings in shares of AbbVie by 5.3% in the 4th quarter. Investment Research Partners LLC now owns 5,109 shares of the company’s stock valued at $1,168,000 after buying an additional 258 shares during the period. Woodley Farra Manion Portfolio Management Inc. raised its holdings in shares of AbbVie by 57.3% in the 4th quarter. Woodley Farra Manion Portfolio Management Inc. now owns 23,199 shares of the company’s stock valued at $5,301,000 after buying an additional 8,453 shares during the period. Cowa LLC raised its holdings in shares of AbbVie by 19.8% in the 4th quarter. Cowa LLC now owns 6,165 shares of the company’s stock valued at $1,409,000 after buying an additional 1,018 shares during the period. Finally, Absolute Capital Management LLC raised its holdings in shares of AbbVie by 18.5% in the 4th quarter. Absolute Capital Management LLC now owns 1,158 shares of the company’s stock valued at $265,000 after buying an additional 181 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Trading Up 0.0%

Shares of NYSE ABBV opened at $225.04 on Friday. The stock has a market cap of $397.60 billion, a P/E ratio of 110.86, a PEG ratio of 0.69 and a beta of 0.32. AbbVie Inc. has a 12-month low of $181.73 and a 12-month high of $244.81. The business’s fifty day simple moving average is $210.80 and its 200-day simple moving average is $219.01.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.06. The business had revenue of $15 billion for the quarter, compared to analysts’ expectations of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The company’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same period last year, the firm earned $2.46 earnings per share. On average, equities analysts forecast that AbbVie Inc. will post 14.3 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on ABBV. Bank of America upgraded AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price objective on the stock in a report on Thursday, April 30th. Evercore set a $235.00 price objective on AbbVie in a report on Friday, May 15th. Canaccord Genuity Group boosted their price objective on AbbVie from $262.00 to $265.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $240.00 price objective on shares of AbbVie in a report on Thursday, April 30th. Finally, DZ Bank upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 30th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $253.43.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Analysts and media coverage highlighted AbbVie’s Skyrizi and Rinvoq as key growth drivers, noting strong first-quarter performance and the potential for continued sales momentum through 2026, including additional indications. Will Skyrizi & Rinvoq Continue to Drive AbbVie’s Topline Through 2026?
• Positive Sentiment: Another market commentary framed AbbVie as a growth-pharma stock at a value-pharma price, reinforcing the view that its earnings growth and pipeline may justify the valuation. AbbVie: Growth-Pharma Profile At A Value-Pharma Price
• Positive Sentiment: AbbVie was also featured on CNBC’s “Final Trades”, which can support investor sentiment by keeping the stock in the market spotlight. AbbVie, Devon Energy and more on CNBC’s ‘Final Trades’
• Neutral Sentiment: Several pieces described AbbVie as a stock worth watching or holding after a strong run, with valuation and balance-sheet concerns tempering enthusiasm but not signaling a major change in the business outlook. Up 45% Since 2024: 1 Glaring Reality That Makes AbbVie Stock a Hold at $225
• Negative Sentiment: AbbVie also faced a FDA Complete Response Letter for its fast-acting neurotoxin TrenibotE, citing manufacturing-related issues. While the letter reportedly raised no safety or efficacy concerns, it delays the program and adds near-term regulatory uncertainty. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.